Vol 49 No 04

Apalutamide survival benefit in mCSPC sustained in long-term follow-up

February 13, 2021

After adjusting for crossover using a preplanned sensitivity analysis, investigators for the pivotal phase 3 TITAN trial found a 48% reduction in the risk of death in patients treated with apalutamide plus ADT versus ADT alone.